Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification

Maria Zanti,Denise G. O'Mahony,Michael T. Parsons,Leila Dorling,Joe Dennis,Nicholas J. Boddicker,Wenan Chen,Chunling Hu,Marc Naven,Kristia Yiangou,Thomas U. Ahearn,Christine B. Ambrosone,Irene L. Andrulis,Antonis C. Antoniou,Paul L. Auer,Caroline Baynes,Clara Bodelon,Natalia V. Bogdanova,Stig E. Bojesen,Manjeet K. Bolla,Kristen D. Brantley,Nicola J. Camp,Archie Campbell,Jose E. Castelao,Melissa H. Cessna,Jenny Chang-Claude,Fei Chen,Georgia Chenevix-Trench,NBCS Collaborators,Don M. Conroy,Kamila Czene,Arcangela De Nicolo,Susan M. Domchek,Thilo Dork,Alison M. Dunning,A. Heather Eliassen,D. Gareth Evans,Peter A. Fasching,Jonine D. Figueroa,Henrik Flyger,Manuela Gago-Dominguez,Montserrat Garcia-Closas,Gord Glendon,Anna Gonzalez-Neira,Felix Grassmann,Andreas Hadjisavvas,Christopher A. Haiman,Ute Hamann,Steven N. Hart,Mikael B.A. Hartman,Weang-Kee Ho,James M. Hodge,Reiner Hoppe,Sacha J. Howell,kConFab Investigators,Anna Jakubowska,Elza K. Khusnutdinova,Yon-Dschun Ko,Peter Kraft,Vessela N. Kristensen,James V. Lacey,Jingmei Li,Geok Hoon Lim,Sara Lindstrom,Artitaya Lophatananon,Craig Luccarini,Arto Mannermaa,Maria Elena Martinez,Dimitrios Mavroudis,Roger L. Milne,Kenneth Muir,Katherine L. Nathanson,Rocio Nunez-Torres,Nadia Obi,Janet E. Olson,Julie R. Palmer,Mihalis I. Panayiotidis,Alpa V. Patel,Paul D.P. Pharoah,Eric C. Polley,Muhammad U. Rashid,Kathryn J. Ruddy,Emmanouil Saloustros,Elinor J. Sawyer,Marjanka K. Schmidt,Melissa C. Southey,Veronique Kiak-Mien Tan,Soo Hwang Teo,Lauren R. Teras,Diana Torres,Amy Trentham-Dietz,Therese Truong,Celine M. Vachon,Qin Wang,Jeffrey N. Weitzel,Siddhartha Yadav,Song Yao,Gary R. Zirpoli,Melissa S. Cline,Peter Devilee,Sean V. Tavtigian,David E. Goldgar,Fergus J. Couch,Douglas F. Easton,Amanda B. Spurdle,Kyriaki Michailidou

DOI: https://doi.org/10.1101/2024.09.04.24313051

2024-09-04

Abstract:Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating patient management. Case-control data is one evidence type used to classify VUS, and previous findings indicate that case-control likelihood ratios (LRs) outperform odds ratios for variant classification. As an initiative of the Evidence‐based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Analytical Working Group we analyzed germline sequencing data of and from 96,691 female breast cancer cases and 303,925 unaffected controls from three studies: the BRIDGES study of the Breast Cancer Association Consortium, the Cancer Risk Estimates Related to Susceptibility consortium, and the UK Biobank. We observed 11,227 and variants, with 6,921 being coding, covering 23.4% of and VUS in ClinVar and 19.2% of ClinVar curated (likely) benign or pathogenic variants. Case-control LR evidence was highly consistent with ClinVar assertions for (likely) benign or pathogenic variants; exhibiting 99.1% sensitivity and 95.4% specificity for and 92.2% sensitivity and 86.6% specificity for . This approach provides case-control evidence for 785 unclassified variants, that can serve as a valuable element for clinical classification.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is a key challenge in hereditary cancer risk assessment: how to classify variants of uncertain significance (VUS) in the BRCA1 and BRCA2 genes. After these variants are found clinically, it is often difficult to conduct effective patient management due to the uncertainty of their association with the disease. To improve this situation, researchers utilized large - scale case - control data and provided more accurate classification basis for these variants by calculating likelihood ratios (LRs).

Specifically, the paper analyzed BRCA1 and BRCA2 gene sequence data from 96,691 female breast cancer patients and 303,925 disease - free female control groups. The main objectives of the study were:

1. **Evaluate and classify VUS**: Provide evidence through large - scale case - control studies to help classify BRCA1 and BRCA2 variants whose current clinical significance is uncertain.
2. **Improve classification accuracy**: Use the likelihood ratio method (instead of the traditional odds ratio method) to improve the accuracy of judging the pathogenicity of variants.
3. **Provide support for clinical applications**: Provide reliable evidence for clinicians and genetic counselors to better manage and guide patients carrying these variants.

Through this method, the research team hopes to reduce the number of VUS and provide more reliable support for clinical decision - making.